MTDH and breast cancer: K-M analysis showed that higher expression level of MTDH accompanied with worse relapse-free survival (RFS, 1.23 [1.02–1.49], p = 0.03, Figure 5C), worse overall survival (OS, 1.18 [1.01–1.38], p = 0.034, Figure 5C), worse disease metastasis-free survival (DMFS, 1.34 [1.21–1.48], p = 1.7E-8, Figure 5C) and worse post-operative progression survival (PPS, 1.28 [1.01–1.62], p = 0.037, Figure 5C) in breast cancer.